Moneycontrol
Mar 08, 2017 04:01 PM IST | Source: PTI

Unichem Labs gets USFDA nod for migraine tablets

The company "has received abbreviated new drug application (ANDA) approval from the United States Food and Drug Administration (USFDA) for Rizatriptan Benzoate ODT, 5mg & 10mg and Rizatriptan Benzoate Tablets USP, 5mg & 10mg...," Unichem Laboratories said in a filing to BSE.

 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Drug firm Unichem Laboratories said today it has received approval from the US health regulator for its Rizatriptan Benzoate tablets used for the treatment of migraine.


The company "has received abbreviated new drug application (ANDA) approval from the United States Food and Drug Administration (USFDA) for Rizatriptan Benzoate ODT, 5mg & 10mg and Rizatriptan Benzoate Tablets USP, 5mg & 10mg...," Unichem Laboratories said in a filing to BSE.


The tablets are generic versions of Merck & Company Inc's Maxalt MLT tablets 5mg & 10mg and Maxalt tablets 5mg, 10mg, it added.


The product will be commercialised from the company's Goa plant. Active Pharmaceutical Ingredient will also be made in-house at Roha API Plant, Unichem Laboratories said.


The tablets are indicated for acute treatment of migraine in adults and in pediatric patients of 6 to 17 years of age.

Shares of Unichem Laboratories were trading at Rs 264.10 in the afternoon trade on BSE, up 0.40 percent from its previous close.

Sections
Follow us on
Available On